"We are encouraged by these initial findings and hope that they contribute to improving outcomes for patients with respiratory insufficiency disease," said Kevin Farberow, DHSc, MBA, SCIO Health Analytics. "Further analysis with regard to healthcare cost utilization in this patient population is underway and we look forward to sharing those results at a forthcoming scientific program."
The 21 patients in the study had a variety of chronic lung diseases: obstructive chronic bronchitis (7 patients); bullous emphysema (5); emphysema and obstructive chronic bronchitis (3); bullous emphysema and alpha-1 antitrypsin deficiency (1); obstructive chronic bronchitis and alpha-1 antitrypsin deficiency (1); emphysema, obstructive chronic bronchitis and alpha-1 antitrypsin deficiency (1); bronchiolitis obliterans (1); emphysema, obstructive chronic bronchitis and bronchiectasis (1); and pulmonary hypertension (1). The mean patient age was 69.7 years, with a mean elapsed time of 14.6 months from diagnosis to initiation of a non-invasive open ventilation system.
Ad Statistics
Times Displayed: 22281
Times Visited: 445 Stay up to date with the latest training to fix, troubleshoot, and maintain your critical care devices. GE HealthCare offers multiple training formats to empower teams and expand knowledge, saving you time and money
"The significant improvements in clinical measures seen in this study are similar to the results we see in the clinic when patients add a portable non-invasive open ventilation system to an existing regimen, that may include pharmacological agents and oxygen therapy," said Larry C. Casey, MD, PhD, Mayo Clinic Health System, Franciscan Healthcare, La Crosse, WI. "Improvements of this magnitude have rarely occurred over the past several decades, and these findings support the use of a portable non-invasive open ventilation system as part of the treatment paradigm for patients living with chronic lung disease."
About Chronic Lung Diseases
Chronic bronchitis, prolonged inflammation of the lining of the airways, or bronchial tubes, and emphysema are commonly referred to as chronic obstructive pulmonary disease (COPD). COPD is a progressive respiratory disease that is estimated to affect 24 million U.S. adults, approximately half of whom are undiagnosed. It is a major cause of disability and the third leading cause of death in the U.S. Alpha-1 antitrypsin deficiency is an inherited disorder that may cause lung disease and liver disease.
About SCIO Health Analytics®
Based in West Hartford, Connecticut, SCIO Health Analytics® is an industry-leading services company that delivers analytic solutions to more than 50 healthcare organizations, including 15 of the top 25 health insurers and life sciences companies. With more than 600 employees and four delivery centers, the company's focus is in the healthcare domain.
